Scopus
YÖKSİS Eşleşti
Rituximab-induced leukocytoclastic vasculitis in a patient with low-grade orbital B-cell lymphoma: a case report
Anti-Cancer Drugs · Ekim 2024
YÖKSİS Kayıtları
Rituximab-induced leukocytoclastic vasculitis in a patient with low-grade orbital B-cell lymphoma: a case report
Anti-Cancer Drugs · 2024 SCI-Expanded
ARAŞTIRMA GÖREVLİSİ NESİME İNCİ GÜNER →
Makale Bilgileri
DergiAnti-Cancer Drugs
Yayın TarihiEkim 2024
Cilt / Sayfa35 · 878-881
Scopus ID2-s2.0-85200506665
Özet
Rituximab is an anti-CD20 chimeric murine/human mAb mainly used to treat certain types of lymphoproliferative malignancies and autoimmune diseases. Although it has been used in the treatment of vasculitis in recent years, it rarely triggers severe vascular skin reactions such as leukocytoclastic vasculitis (LCV). Physicians should be aware of this rare adverse event that requires discontinuation of rituximab, which can occur days or even weeks after rituximab treatment. Here, we report a case of LCV observed in a patient with low-grade orbital B-cell lymphoma treated with weekly rituximab and local radiotherapy. In our case, discontinuation of rituximab and initiation of oral methylprednisolone therapy were sufficient to achieve complete resolution of the LCV.
Yazarlar (4)
1
Nesime İnci Güner
ORCID: 0000-0002-2192-1066
2
Ömer Dizdar
ORCID: 0000-0003-0911-9078
3
Alev Türker
4
Aygin Bayraktar-Ekincioglu
Anahtar Kelimeler
cell lymphoma
drug
grade orbital B
induced leukocytoclastic vasculitis
low
rituximab
Kurumlar
Hacettepe Üniversitesi
Ankara Turkey